Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage

Exclusion Criteria

• •Intracerebral hemorrhage attributed to other causes (e.g., cerebral aneurysm, cerebrovascular malformation, brain tumor, cerebral venous sinus thrombosis, hemorrhagic transformation of ischemic stroke, head trauma, anticoagulation therapy, hematologic disorders).
• •Hemorrhage located in the infratentorial region.
• •Hemorrhage confined primarily to the ventricular system.
• •Clinical signs or symptoms suggestive of brain herniation (e.g., progressive decline in level of consciousness, diminished or absent pupillary light reflexes, bilateral pyramidal signs).
• •Severe cardiac dysfunction (NYHA Class III or IV).
• •High-risk chronic arrhythmias (e.g., sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia-related syncope without pacemaker implantation).
• •Severe hepatic impairment defined as ALT \>2x ULN or AST \>2x ULN (ULN = Upper Limit of Normal).
• •Severe renal impairment defined as serum creatinine \>1.5x ULN.
• •History of severe asthma or chronic obstructive pulmonary disease (COPD).
• •History of coagulopathy or systemic bleeding disorder.
• •Leukopenia (\<2 × 10⁹/L) or thrombocytopenia (\<100 × 10⁹/L).
• •Patients scheduled for surgical intervention (including, but not limited to, hematoma evacuation \[minimally invasive or conventional\], decompressive craniectomy, hematoma aspiration, or external ventricular drainage) prior to the first dose of study treatment.
• •Pre-stroke modified Rankin Scale (mRS) score \>2.
• •Presence of other severe disease resulting in a life expectancy of less than 1 year.
• •Inability to understand the study procedures and/or complete follow-up due to psychiatric illness, cognitive impairment, or emotional disorders.
• •Women who are pregnant or lactating.
• •Participation in another clinical trial within the past 3 months or current participation in another clinical trial.